179 related articles for article (PubMed ID: 22486895)
1. Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, β-nicotyrine and menthol.
Kramlinger VM; von Weymarn LB; Murphy SE
Chem Biol Interact; 2012 May; 197(2-3):87-92. PubMed ID: 22486895
[TBL] [Abstract][Full Text] [Related]
2. (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6.
Khojasteh-Bakht SC; Koenigs LL; Peter RM; Trager WF; Nelson SD
Drug Metab Dispos; 1998 Jul; 26(7):701-4. PubMed ID: 9660853
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based inactivation of cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus constituents.
Pouyfung P; Prasopthum A; Sarapusit S; Srisook E; Rongnoparut P
Drug Metab Pharmacokinet; 2014; 29(1):75-82. PubMed ID: 23903410
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
Stephens ES; Walsh AA; Scott EE
Drug Metab Dispos; 2012 Sep; 40(9):1797-802. PubMed ID: 22696418
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism.
von Weymarn LB; Brown KM; Murphy SE
J Pharmacol Exp Ther; 2006 Jan; 316(1):295-303. PubMed ID: 16188955
[TBL] [Abstract][Full Text] [Related]
6. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6.
Denton TT; Zhang X; Cashman JR
Biochem Pharmacol; 2004 Feb; 67(4):751-6. PubMed ID: 14757175
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach.
Chiang HC; Wang CY; Lee HL; Tsou TC
Toxicol Appl Pharmacol; 2011 Jun; 253(2):145-52. PubMed ID: 21473878
[TBL] [Abstract][Full Text] [Related]
8. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes.
DeVore NM; Scott EE
J Biol Chem; 2012 Aug; 287(32):26576-85. PubMed ID: 22700965
[TBL] [Abstract][Full Text] [Related]
9. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
10. Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.
Megaraj V; Zhou X; Xie F; Liu Z; Yang W; Ding X
Carcinogenesis; 2014 Jan; 35(1):131-7. PubMed ID: 23917075
[TBL] [Abstract][Full Text] [Related]
11. CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine Δ5'(1')iminium ion.
von Weymarn LB; Retzlaff C; Murphy SE
J Pharmacol Exp Ther; 2012 Nov; 343(2):307-15. PubMed ID: 22869927
[TBL] [Abstract][Full Text] [Related]
12. Synthetic models related to methoxalen and menthofuran-cytochrome P450 (CYP) 2A6 interactions. benzofuran and coumarin derivatives as potent and selective inhibitors of CYP2A6.
Yamaguchi Y; Akimoto I; Motegi K; Yoshimura T; Wada K; Nishizono N; Oda K
Chem Pharm Bull (Tokyo); 2013; 61(10):997-1001. PubMed ID: 23902929
[TBL] [Abstract][Full Text] [Related]
13. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Zhang X; D'Agostino J; Wu H; Zhang QY; von Weymarn L; Murphy SE; Ding X
J Pharmacol Exp Ther; 2007 Nov; 323(2):570-8. PubMed ID: 17671098
[TBL] [Abstract][Full Text] [Related]
14. Computational insights into the different catalytic activities of CYP2A13 and CYP2A6 on NNK.
Xu Y; Shen Z; Shen J; Liu G; Li W; Tang Y
J Mol Graph Model; 2011 Sep; 30():1-9. PubMed ID: 21680215
[TBL] [Abstract][Full Text] [Related]
15. Structure of the human lung cytochrome P450 2A13.
Smith BD; Sanders JL; Porubsky PR; Lushington GH; Stout CD; Scott EE
J Biol Chem; 2007 Jun; 282(23):17306-13. PubMed ID: 17428784
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea.
Boonruang S; Prakobsri K; Pouyfung P; Srisook E; Prasopthum A; Rongnoparut P; Sarapusit S
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):1136-1142. PubMed ID: 28856944
[TBL] [Abstract][Full Text] [Related]
17. Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers.
von Weymarn LB; Chun JA; Hollenberg PF
Carcinogenesis; 2006 Apr; 27(4):782-90. PubMed ID: 16364922
[TBL] [Abstract][Full Text] [Related]
18. Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13.
Jalas JR; Ding X; Murphy SE
Drug Metab Dispos; 2003 Oct; 31(10):1199-202. PubMed ID: 12975327
[TBL] [Abstract][Full Text] [Related]
19. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Su T; Bao Z; Zhang QY; Smith TJ; Hong JY; Ding X
Cancer Res; 2000 Sep; 60(18):5074-9. PubMed ID: 11016631
[TBL] [Abstract][Full Text] [Related]
20. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes.
Brown PJ; Bedard LL; Reid KR; Petsikas D; Massey TE
Drug Metab Dispos; 2007 Nov; 35(11):2086-94. PubMed ID: 17717079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
